Beam Therapeutics Inc. Common Stock (BEAM) Financials
Key financial figures for Beam Therapeutics Inc. Common Stock (Q2 2026).
Beam Therapeutics Inc. reported revenue of $490.0 thousand for Q2 FY2026, down 94.2% from the same period a year earlier. The company posted a net loss of $122.7 million, or -$1.18 per share. Operating margin came to -25827.14%, against -1419.22% a year earlier. Free cash flow for the period was -$68.5 million. Across the last 5 reported quarters, quarterly revenue has moved from $8.5 million in Q2 FY2025 to $490.0 thousand in Q2 FY2026. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Beam Therapeutics Inc. are on the SentiSense financials page.
- Revenue
- $490K
- Net Income
- -$123M
- EPS
- $-1.18
- Total Assets
- $1.4B
- Operating Cash Flow
- -$66M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $490K | -$123M | -$1.18 | -25827.14% | -$69M |
| Q1 FY2026 | $32M | -$94M | -$0.91 | -337.81% | -$131M |
| Q4 FY2025 | $114M | $244M | $2.33 | -15.29% | -$87M |
| Q3 FY2025 | $10M | -$113M | -$1.10 | -1307.6% | -$86M |
| Q2 FY2025 | $8M | -$102M | -$1.00 | -1419.22% | -$80M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $140M | -$80M | -$0.81 | -274.57% | -$360M |
| FY2024 | $64M | -$377M | -$4.58 | -654.25% | -$356M |
| FY2023 | $378M | -$133M | -$1.72 | -46.73% | -$183M |
Frequently asked questions
What was Beam Therapeutics Inc.'s revenue last quarter?
Beam Therapeutics Inc. reported revenue of $490.0 thousand for Q2 FY2026, down 94.2% from the same period a year earlier.
Is Beam Therapeutics Inc. profitable?
Not in its most recent reported period. Beam Therapeutics Inc. reported a net loss of $122.7 million for Q2 FY2026, a net margin of -25036.33% on revenue.
How has Beam Therapeutics Inc.'s margin trended?
Operating margin was -25827.14% in Q2 FY2026, compared with -1419.22% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Beam Therapeutics Inc. generate?
Beam Therapeutics Inc. generated free cash flow of -$68.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Beam Therapeutics Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.